Lesley Seymour
Queen's University
H-index: 79
North America-Canada
Top articles of Lesley Seymour
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227 … | Revue des Maladies Respiratoires Actualités | L Greillier M Locatelli Sanchez Q Chu F Perrone G Zalcman | 2024/1/1 |
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop … | JCO Precision Oncology | Erica C Nakajima Amber Simpson Jan Bogaerts Elisabeth GE de Vries Richard Do | 2024/4 |
Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response | Clinical Cancer Research | Lalitha K Shankar Erich Huang Saskia Litiere Otto S Hoekstra Larry Schwartz | 2023/1/4 |
Towards evidence-based response criteria for cancer immunotherapy | Scott Laurie Lesley Seymour Elisabeth de Vries Elena GARRALDA | 2023/5/24 | |
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and … | Quincy S Chu Maria Carmela Piccirillo Laurent Greillier Federica Grosso Giuseppe Lo Russo | 2023/6/10 | |
Oncology phase I trial design and conduct: time for a change-MDICT Guidelines 2022 | D Araujo A Greystoke S Bates A Bayle E Calvo | 2023/1/1 | |
Abstract P3-07-18: CCTG IND. 239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC) | Cancer Research | John Hilton David W Cescon Andrew Robinson Sukhbinder Dhesy-Thind Sara Taylor | 2023/3/1 |
Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada. | Mariam Jafri Corey Willman Alison May Urton Jan-Willem Henning Lesleigh S Abbott | 2023/6/1 | |
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial | The Lancet | Jong-Mu Sun Lin Shen Manish A Shah Peter Enzinger Antoine Adenis | 2021/8/28 |
Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND. 237 | Cancer Research | David W Cescon John Hilton Philippe Bedard Phillip Blanchette Rossanna C Pezo | 2023/3/1 |
A phase II study of durvalumab re-treatment+/-prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND. 238A). | Peter Michael Ellis Sara Kristina Taylor Penelope Ann Bradbury John R Goffin Rosalyn A Juergens | 2023/6/1 | |
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance | bmj | Christina Yap Olga Solovyeva Johann De Bono Jan Rekowski Dhrusti Patel | 2023/10/20 |
Abstract P3-07-10: CCTG IND. 236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC) | Cancer Research | Philippe Bedard Mihaela Mates John Hilton Nathalie Levasseur Arif Awan | 2023/3/1 |
Response to a Letter Received Entitled:“‘Brief Report: Canadian Cancer Trials Group IND. 227’: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced … | Journal of Thoracic Oncology | Maria Carmela Piccirillo Quincy Chu Penelope Bradbury Lesley Seymour | 2023/6/1 |
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance | bmj | Christina Yap Jan Rekowski Moreno Ursino Olga Solovyeva Dhrusti Patel | 2023/10/20 |
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study. | Edmond Michael Kwan Moira Katherine Rushton Wilson Tu Sebastien J Hotte Som D Mukherjee | 2023/2/20 | |
Brief report: canadian cancer trials group IND. 227: A phase 2 randomized study of pembrolizumab in patients with advanced Malignant pleural mesothelioma (NCT02784171) | Journal of Thoracic Oncology | Maria Carmela Piccirillo Quincy Chu Penelope Bradbury Wei Tu Courtney H Coschi | 2023/6/1 |
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data | Clinical Lung Cancer | Prashanth Ashok Kumar Maryam Karimi Alina Basnet Lesley Seymour Robert Kratzke | 2023/9/1 |
iRECIST and atypical patterns of response to immuno-oncology drugs | Jorge Luis Ramon-Patino Sabine Schmid Sally Lau Lesley Seymour Pierre-Olivier Gaudreau | 2022 | |
Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG … | European Journal of Cancer | M Rushton D Cescon J Hilton P Bedard P Blanchette | 2022/10/1 |
